Skip to main content
Blizard Institute - Barts and The London

Dr Paul Allen, MSc, PhD


SMD Deputy Dean for Postgraduate Research (PGR)

Centre: Centre for Genomics and Child Health

Telephone: 020 7882 2279



Dr Paul Allen has been employed at Barts and The London School of Medicine and Dentistry, Whitechapel since February 1989. He was appointed to lecturer in November 1998, senior lecturer in October 2003 and Reader in January 2014. He is  interested in apoptosis, the cell cycle and mitotic catastrophe in the context of leukaemia and leukaemia therapies. He has developed skills in flow cytometry and cell sorting particularly with respect to the cell cycle and cell death.

In 1988, he moved to the Bone Marrow Transplant Team in the Department of Chemical Immunology at The Westminster Hospital.

Prior to this Dr Allen worked at the CRC Laboratories, Medical Oncology, Charing Cross and Westminster Medical School under Prof Kenneth Bagshaw. He was involved in cancer diagnostic, monoclonal antibody production and was part of a larger team involved in drug development, drug targeting, radio-imaging and disease monitoring.
Dr Paul Allen was appointed to the post of Director, Blizard Institute Graduate Studies (Research Degrees) in January 2007.
He took responsibility for the intercalated degree in Experimental Pathology in September 2010 and Chair of the Intercalated Degrees Committee from January 2016



Dr Paul Allen sits  on a range of committees at institute, school and college level relating to undergraduate and postgraduate teaching and supervision.



I am director of graduate studies for research degrees in the Blizard Institute and I look after all aspects of research degrees in our institute.

I am also co-ordinator of the intercalated BSc degree in Experimental Pathology.


Intercalated BSc in Experimental Pathology.

Chair Intercalated Degrees Committee

PhD supervison and examination




Research Interests:

Dr Paul Allen's Research Interests is in apoptosis, mitotic catastrophe, cell cycle regulation and polyploidisation in megakaryocytes.



DA McCarthy, MG Macey and PD Allen. A Simple Novel Procedure for Monitoring Membrane Scrambling and Permeability in Microparticle, Platelets and Leukocytes in Whole Blood Samples. Exp Haem 2008; 36: 909-921.

Higginbottom, U Jahnke, A C Newland, FE Cotter and PD Allen. New Alternative Phosphorylation sites on the cyclin dependent kinase 1/cyclin A complex in p53 deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis. Apoptosis 2007; 12:1847-1855.

U Jahnke, K Higginbottom, AC.Newland, FE.Cotter and PD.Allen. Cell Death in Leukaemia: Passenger Protein Regulation by Toposiomerase Inhibitors. Biochem. Biophys. Res. Comm. 2007; 361(4) 928-933

SJ Strauss, K. Higginbottom, L Maharaj, PD Allen, D Schenkein, TA Lister and SP Joel. The proteosome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. 2007; 67: 2783-2790.

K Higginbottom, M Cummings, AC Newland and PD Allen. Etoposide-Mediated Deregulation of the G2M Checkpoint in Myeloid Leukaemic Cell Lines Results in Loss of Cell Survival. Br J. Haemat. 2002; 119:956-964.

M Cummings, T Siitonen, K Higginbottom, AC Newland and PD Allen. P53-mediated down-regulation of Chk1 abrogates the DNA damage induced G2M checkpoint in K562 cells, resulting in increased apoptosis. Br. J. Haemat 2002; 116: 421-428.

NJ Ketley, PD Allen, SM Kelsey and AC Newland. Mechanisms of resistance to apoptosis in human AML blasts: the role of differentation-induced perturbations of cell cycle checkpoints. Leukemia. 2000; 14:620-628

Y Yin, PD Allen, L Jia, MG Macey, SM Kelsey and AC Newland. Constitutive levels of cAMP-dependent protein kinase activity determine sensitivity of human multidrug resistant leukemia cell lines to growth inhibition and apoptosis by forskolin and tumour necrosis factor alpha. Br. J. Haemat. 2000; 108:565-573.

Y-L WU, X-R Jiang, DM Lillington, PD Allen, AC Newland and SM Kelsey. 1,25 Dihydroxyvitamin D3 protects human leukemic cells from tumour necrosis factor-induced apoptosis via inactivation of cytosolic phospholipase A3. Cancer Research, 1998; 58:633-640.

L Jia, PD Allen MG Macey, MF Grahn, AC Newland and SM Kelsey. Mitochondrial electron transport chain but not ATP synthesis is required for drug induced apoptosis in human leukaemic cells; a possible novel mechanism of regulating drug resistance. Br J. Haemat. 1997; 98:686-698.

L Jia, RR Dourmashkin, PD Allen, AB Gray, AC Newland and SM Kelsey. Inhibition of autophagy abrogates tumour necrosis factor alpha induced apoptosis in human T-lymphoblastic leukaemic cells. 1997. Br. J. Haemat. 98: 673-685.

NJ Ketley, PD Allen, SM Kelsey and AC Newland. Modulation of idarubicin induced apoptosis in human AML blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3 and granulocyte-macrophage colony stimulating factor. Blood, 1997; 90:4578-4587.


View all Paul Allen's Research Publications at: